anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide a base cosmetic giving a shadowed steric feeling to a finishing cosmetic such as foundation coated on the base cosmetic and having excellent effect to form shapely face line, nose, etc. CONSTITUTION:The objective base cosmetic for conditioning the state of the skin by applying to the skin before the application of a make-up cosmetic such as foundation contains a mica titanium pigment colored essentially with a titanium suboxide and free from interference color as an essential component in an amount of preferably 0.5-10wt.% (especially 1-7wt.%) based on the total base cosmetic. It gives a delicate change to the massive feeling of the skin finished with a foundation, etc., applied to the base cosmetic layer. A steric feeling is imparted by applying a shadow to the finished skin. The mica constituting the pigment has a particle diameter of about 1-50mum and the particle has preferably flat shape as far as possible. The coating amount of the titanium suboxide is preferably 0.01-50 pts.wt. based on 100 pts.wt. of the mica. The titanium suboxide may be used in combination with 0-50 pts.wt. of titanium dioxide.
Chagas disease is a major cause of heart disease, morbidity, and premature loss of life in the Americas. Eliminating the Trypanosoma cruzi parasite using antitrypanosomal drugs has shown to produce cure in children, halt future congenital transmission, and reduce morbidity from the disease. However, the current treatment regimens are lengthy (60 days) and entail frequent side effects, causing about 20% of patients to drop out of treatment, and discouraging others from starting. Recent research found that a reduced treatment of benznidazole still has adequate efficacy with few side effects.

In this international, multicenter, double-blind, phase III, placebo-controlled study, 672 participants will be randomly assigned to receive the standard-dose of benznidazole (300 mg daily for 8 weeks) or the short experimental regimens (benznidazole 300 mg daily for the first 2 weeks plus placebo for the last 6 weeks or benznidazole 300 mg daily for the first 4 weeks plus placebo for the last 4 weeks). Efficacy will be assessed considering a non-inferiority design and through the detection of parasite deoxyribonucleic acid (DNA) through molecular biology (Polymerase Chain Reaction - PCR). Meanwhile, safety will be evaluated through a superiority design, with the aim to find the new regimen as effective as the standard one, but superior in terms of safety. An intention-to-treat analysis will be performed, and statistical significance will be set at 0.025 for the non-inferiority outcome (positive PCR) and 0.05 for the superiority outcome.

The study population will be adult participants, 18 years or older, with chronic Chagas disease in its indeterminate or mild cardiac forms, with a positive diagnosis from two serological assays. The trial will be conducted in four sites: two in Bolivia, and two in Colombia. The primary endpoint will be parasitological response determined as sustained negative qualitative PCR at 24 months after treatment. The proportion of participants with positive qualitative PCR will be measured at 1, 4, 6, 8, 12, 18, and 24 months from end of treatment. The frequency of adverse events leading to treatment discontinuation will be compared. An economic evaluation will be conducted assessing the direct and indirect costs, including procedures associated with the management of adverse events.
The invention discloses an aptamer IDC-31 molecular probe for specifically identifying serum of breast invasive ductal carcinoma and application thereof, belonging to the field of molecular biomedicine. The nucleotide sequence of the aptamer IDC-31 is shown as SEQ ID NO. 1. The IDC-31 specific sequence designed by the invention can specifically identify the serum of the breast invasive ductal carcinoma by adopting a method of modifying and marking (such as site, biotin, fluorescein or digoxin and the like) at the 5 'end or the 3' end. IDC-31 is used as a probe molecule or a detection index for the basic research of auxiliary diagnosis, treatment or monitoring prognosis of the breast invasive ductal carcinoma, and is used as a non-invasive detection molecule for the auxiliary diagnosis and tumor biological guide treatment of clinical breast invasive ductal carcinoma serum samples. The method is simple, rapid and sensitive, and has wide clinical application and basic application prospect.
Niraparib (200mg or 300 mg based on body weight and blood platelet count), oral, once daily. Bevacizumab (15 mg/kg, IV on day 1 of each cycle).
Objective Bronchoscopic lung volume reduction (BLVR) using a one-way endobronchial valve (EBV) can provide clinically meaningful benefits to chronic obstructive pulmonary disease (COPD) patients. Although the Japanese Pharmaceuticals and Medical Devices Agency approved EBVs in November 2022, information regarding the number of Japanese patients with severe COPD eligible for BLVR treatment is still lacking. We therefore screened computed tomography (CT) images of patients with severe COPD using a quantitative CT (QCT) analysis to estimate the proportion of candidates eligible for BLVR treatment with an EBV. Methods CT scans of COPD patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages 3 and 4 were retrospectively analyzed using QCT to evaluate fissure integrity and tissue destruction. The difference in volume-weighted percentage was measured using the density scores of the target lobe and ipsilateral non-target lobe at -910 Hounsfield units. The target lobe was defined as the most affected lobe, with an emphysema destruction score of >50% for each patient. Results High-resolution CT scans of 32 patients (GOLD 3=19, GOLD 4=13) were analyzed. The target lobe could not be identified in 1 patient, whereas the target lobes for 8 patients were not surrounded by fissures with ≥80% completeness. Conversely, in 13 patients, the target lobes were surrounded by fissures with >95% completeness. The remaining 10 patients had fissure completeness between 80% and 95% at the target lobes and were considered candidates for collateral ventilation assessment. Conclusion A QCT analysis showed that 23 of 32 patients with severe COPD could be considered for a thorough examination of BLVR treatment with EBV.
PURPOSE:To obtain a preparation for ophthalmic administration, having high transferability to protomerite and useful for the remedy of inflammation of conjunctiva and ectocornea in ophthalmic field, by adding flurbiprofen (FP) to fat emulsion. CONSTITUTION:Soybean oil is mixed with phospholipid and FP [2-(2-fluoro-4- biphenylyl)propionic acid] or its derivative and, if necessary, with an additive such as emulsifying assistant, stabilizer, etc., at prescribed ratios. The mixture is heated to obtain a solution, homogenized to a W/O-type dispersion with a homogenizer, added with a prescribed amount of water and homogenized again to convert the dispersion to an O/W-type emulsion and obtain an FP- containing fat emulsion having average particle diameter of preferably <=1.0mu (particle size distribution of 0.1-1.0mu). The composition of the emulsion is preferably 0.01-1(W/V)% FP, 1-20% soybean oil and 5-30pts. of phospholipid based on 100pts. of soybean oil.
Submission of Audit-C questionnaire to all the patients of the study. When the result to the AUDIT-C questionnaire reaches at least 1 point, the analysis of the Carbohydrate deficient transferrin (CDT) is performed within 3 days after the beginning of the study. Results of Gamma glutamyl transpeptidase (GGT) and Mean Corpuscular Volume (MCV) performed as routine practice collected at the same time as the CDT analysis.
Participants will undergo 4 weeks (20 sessions) of experimental rehabilitation in their home. They will play custom therapeutic games that are intensive and adapt to their condition. Before and after the 4-week intervention participants will travel to Kessler Foundation to undergo evaluations. The therapy is designed to improve arm range, strength, endurance, as well as memory, focusing and decision making. Data will be stored on the cloud, protected and monitored by the research team.
A first electronic device is disclosed. The first electronic device comprises an interface; microphone circuitry; memory circuitry; and processor circuitry. The first electronic device is configured to discover, via the interface, a first wireless network. The first electronic device is configured to receive, via the interface, from a second electronic device discovering the first wireless network, a voice biometric indicative of a second user. The first electronic device is configured to activate the microphone circuitry to detect an input audio signal. The first electronic device is configured to determine whether the detected input audio signal satisfies one or more criteria. The first electronic device is configured to, when the detected input audio signal satisfies the one or more criteria, determine a parameter indicative of a level of risk of exposure; and generate, based on the parameter, contact data.
NEW MATERIAL:4-Aminocotinine shown by the formula I. USE:White crystal, compound having 195-196 deg.C melting point, and specific rotatory power [alpha]<25>2=-117.9 (c=2.2, MeOH), useful as an artificial antigen for nicotine, having pyridine ring, pyrrolidine ring, and optical activity important as an artificial antigen for nicotine. PREPARATION:Cotinine shown by the formula II is oxidized with a peracid such as H2O2, etc. to form cotinine-N-oxide shown by the formula III, which is reacted with concn. sulfuric acid and fuming sulfuric acid, nitrated, to give 4-nitrocotinin-N-oxide shown by the formula IV. This compound is reduced with iron in acetic acid to give easily the compound shown by the formula I.
Healthy overweight (body mass index, BMI, between 25.0 - 30 kg/m2) between 18 to 45 years old regardless of gender will be recruited. They will be randomly assigned to receive two energy balls containing 30 grams of wheat germ or corn meal (control) in a 4-wk randomized controlled pilot trial. The energy balls will contain wheat germ or corn meal, peanut butter, honey and milk. Participants will be asked to consume two energy balls daily for 4 weeks. Anthropometric measures, questionnaires (medical, diet, physical activity and bowel habits), blood and fecal samples will be collected at baseline and at the end of the four week study. The investigator's primary outcome variables will be changes in fecal bacteria, immunoglobulin A, zonulin and short chain fatty acids while secondary outcome variables will be alterations in plasma markers of inflammation and insulin resistance.
Protocol of therapeutic exercises + placebo transcranial electrical stimulation of 8 weeks duration (24 supervised sessions). The program will consist of exercises to strengthen the RM and the scapulothoracic muscles, but the CG will perform the RM strengthening exercises while receiving placebo a-tDCS.
Participants received etanercept 50 mg by subcutaneous injection twice per week (BIW) for the first 12 weeks of the study. From Week 12 to Week 24, participants received etanercept 50 mg once per week (QW) and placebo once per week.
BACKGROUND: Very little information is currently available on the use and outcomes of venovenous bypass (VVB) in liver transplantation (LT) in adults in Australia. In this study, we explored the indications, intraoperative course, and postoperative outcomes of patients who underwent VVB in a high-volume LT unit.
METHODS: The study was a single-center, retrospective observational case series of adult patients who underwent VVB during LT at Austin Health in Melbourne, Australia between March 2008 and March 2022. Information on baseline preoperative status and intraoperative variables, including specific VVB characteristics as well as postoperative and VVB-related complications was collected. The lengths of intensive care unit and hospital stays as well as intraoperative and in-hospital mortality were recorded.
RESULTS: Of the 900 LTs performed at this center during the aforementioned 14-year period, 27 (3%) included a VVB procedure. VVB was performed electively in 16 of these 27 patients (59.3%) and as a rescue technique to control massive bleeding in the other 11 (40.1%). The median (interquartile range [IQR]) age of those who underwent VVB procedures was 48 (39-55) years; the median age was 56 (47-62) years in the non-VVB group (p<0.0001). The median model for end-stage liver disease (MELD) scores were similar between the two patient groups. Complete blood data was available for 622 non-VVB patients. Twenty-six VVB (96.3%) and 603 non-VVB (96.9%) patients required intraoperative blood transfusions. The median (IQR) number of units of packed red blood cells transfused was 7 (4.8-12.5) units in the VVB group compared to 3.0 units (1.0-6.0) in the non-VVB group (p<0.0001). Inpatient mortality was 18.5% and 1.1% for the VVB and non-VVB groups, respectively (p<0.0001). There were no significant differences in length of hospital stay or incidence of acute kidney injury, primary graft dysfunction, or long-term graft failure between the two groups. Patients in the VVB group experienced a higher rate of postoperative non-anastomotic biliary stricture compared to patients in the non-VVB group (33% and 7.9%, respectively; p = 0.0003).
CONCLUSIONS: VVB continues to play a vital role in LT. This case series highlights the heightened risk of major complications linked to VVB. However, the global transition to selective use of VVB underscores the urgent need for collaborative multi-center studies designed to address outstanding questions and parameters related to the safe implementation of this procedure.
PURPOSE: A pharmaceutical composition containing cyclic ADP ribose and a derivative thereof or CD38 is provided to control fertilization ability of sperm. CONSTITUTION: A pharmaceutical composition for promoting fertilization contains cyclic ADP ribose or derivative thereof. The pharmaceutical composition contains CD38(ADP ribosyl cyclase). The cyclic ADP ribose is synthesized by ADP ribosyl cyclase. A prostasome contains the ADP ribosyl cyclase. A method for promoting fertilization by enhancing motility of sperm comprises a step of promoting the synthesis of cyclic ADP ribose. A pharmaceutical composition for contraception contains an antagonist of cyclic APD ribose.
Type 2 diabetes prevalence in adults has grown in the last years in many societies, accompanying the high incidence of obesity-related and other cardiovascular risk factors. Indeed, obesity is the most relevant overnutrition disease worldwide, being more dramatic than a self-esteem problem or an aesthetic issue, since it is associated to different metabolic disorders such as coronary diseases, hypertension, certain tumors, dislipidemia, biliary disorders, immunodeficiencies and insulin resistance. Different studies have shown the efficacy of low-fat diets on weight reduction, which has been associated to an improvement in overweight-related chronic pathological conditions. Additionally, a moderate increase of protein content (up to 30% of total caloric intake) in the diet and the inclusion of low-glycemic index products have been shown as a good tool for weight loss and maintenance. Recent studies have also shown the benefits of partial nutritional interventions, mainly on modifying breakfast intake, on anthropometrical and cardiovascular risk factors in overweight patients.

The study has been designed as a longitudinal nutritional intervention with two consecutive 4-week periods: from week 0 to 4, volunteers will follow their habitual diet. The second period (week 4 to 8), the volunteers' habitual breakfast, mid-morning and afternoon snacks will be substituted by 40-30-30 products, without changing any other parameter of their habitual diet or lifestyle.
Polynucleotides, expression constructs, compositions, kits and method relating to genetic disorders are disclosed. Some embodiments provided herein encompass variants of a protein that relate to a genetic disorder. Also contemplated are expression constructs that encode highly functional and/or stable protein variants. Also described herein are expression constructs that encode protein variants with reduced activity and/or stability. Also described herein are compositions, kits and methods for diagnosing and treating the genetic disorder. In some embodiments, the variants can relate to the treatment and/or diagnosis of genetic disorders.
The invention relates to a traditional Chinese medicine powder for treating a respiratory disease of poultry. The traditional Chinese medicine powder is prepared by the following raw materials in parts by weight: 2-5 parts of longhairy antenoron herb, 5-9 parts of folium isatidis, 1-10 parts of folium eriobotryae, 2-9 parts of plantain seed, 5-9 parts of ephedra, 5-9 parts of fructus forsythiae, 1-4 parts of semen armeniacae amarae, and 1-9 parts of liquorice. A preparation method comprises the following steps of: smashing and uniformly mixing the eight raw materials. The beneficial effects are that: the ephedra capable of inducing sweat, dispelling exogenous evils, freeing lung and relieving asthma is utilized to combined with the liquorice and the semen armeniacae amarae, so that the curative effects on treating cough, asthma, excessive phlegm and fluid retention are enhanced; the plantain seed is selected to be combined with the longhairy antenoron herb, so that the heat-removing effect is obvious; the folium eriobotryae can be used for removing heat from the lung to relieve cough, calming the adverse-rising energy and controlling nausea and vomiting, and has no toxic and side effect; and the fructus forsythiae is combined with the folium isatidis, so that the pharyngalgia and the pyreticosis can be treated. The prepared powder can be easily fed. When the poultry use the powder, drug resistance cannot be generated, and especially after chickens take the powder, residuals are free in vivo, so that the food safety of people can be effectively ensured.
The lymph node involvement in the posterior to level V (PLV) region is mainly observed in nasopharyngeal carcinoma (NPC). Recently, we have reported the distribution of metastatic lymph nodes in the PLV region and there are correlations between the neck node levels (NNL) of NPC, but what is the boundary of the PLV region and how to delineate it remains unclear, and we further to elaborate whether the bilateral level Va should be covered as intermediate-risk nodal regions (CTVn2, about 60 Gy equivalent) for all T and N categories based on these correlations. A total of 1021 consecutive NPC patients with N1-3 stage from January 2012 to December 2020 were reviewed. The lymph node metastasis level of each patient was evaluated according to the updated guidelines proposed in 2013. According to the distribution pattern of lymph node metastasis and the anatomical structure in the PLV region, the boundaries of PLV region was delineated, and whether it is appropriate to cover the bilateral level Va as CTVn2 for all the NPC patients was further discussed. The correlations of level Va with other NNL were studied using logistic regression model. The cranial boundary of PLV region is the caudal border of cricoid cartilage, the caudal boundary is the plane serratus anterior muscle begins to appear, the anterior boundary is the anterior border of trapezius, and the posterior boundary is the convergence of levator scapulae and trapezius. Laterally, the PLV region is limited by the medial edge of trapezius and medially by the lateral surface of levator scapulae. The nodal spread in level Va is based on the lymph node metastasis of level IIb in NPC. The PLV region is a missing NNL of head and neck tumors, especially in NPC. The proposed boundaries of the PLV region can provide a preliminary proposal for the further revision of NNL in head and neck tumors. It is theoretically feasible to reduce the prophylactic irradiation dose of the bilateral level Va in patients with N0 stage or with isolated metastases in level VIIa.
Systems and techniques are disclosed for generating and transferring pose information in three- dimensional (3D) representations of oral care data. The method involves receiving reference 3D representations and trial 3D representations of oral care data using processing circuitry of a computing device. Pose transfer neural networks are executed to assign pose information from the reference 3D representations onto the trial 3D representations. By incorporating the assigned pose information, one or more resulting 3D representations of oral care data are generated, wherein aspects of the trial 3D representations are modified to generate the resulting 3D representations. These resulting 3D representations, enriched with pose information, are then provided to one or more automated processes. These systems and techniques enable accurate and efficient analysis of oral care data, facilitating improved treatment planning and decision-making in the field of oral healthcare.
Stroke is the second cause of death and the third cause of disability worldwide. It leads towards severe disability having a great impact upon independent activities of daily living. Postural stability and balance is often affected by strokes. Balance is a complex function with dynamic and static components. It is a major determinant of community ambulation and gait performance following strokes. Falls in post-stroke patients commonly occur due to impairment of balance. Hence, one of the primary objectives in stroke rehabilitation is to restore postural stability and functional balance, which is a combination of dynamic, static and reactive balance. For improving postural stability and balance one such technique is the utilization of a rocker board, where a platform positioned on an unstable surface is used to challenge balance. Whilst rocker boards have been used effectively for, postural stability, injury prevention, rehabilitation and balance enhancement. Improvements in rocker board performance may be attributable to one or more of the following: muscle strengthening, enhanced intersegmental coordination, increase in brain activity in the supplementary motor area and/or enhanced feed-forward and feed-backward postural control mechanisms. Postural instability limits lower limb functional activities, hence; rapid and optimal improvement of postural control in stroke patients is essential for their independence, social participation and general health. Improvement in postural stability have a great impact upon balance and gait. Rocker board training is also effective for gait and trunk balance in stroke patients. Postural stability increases due to unstable surface because perturbations felt by patients and consequent trails to compensate while doing exercises on the tilted Rocker Board activate the motor system of the patients. Neural plasticity may be enhanced by regular and repeated administration of this training. The trunk exercises on an unstable surface sensitize the muscle spindle through gamma motor neurons, thereby improving motor output which influences the stability of joint. Exercises on an unstable surface increases the external swing which more effectively encourages postural orientation by forcing faster modifications of the sensory and motor systems and also assists in the postural strategy of self-postural control. The trunk stabilization in stroke patients in an important prognostic factor of the recovery of balance ability and functional ambulation. The gait and balance improvement is because the motor cortex precedes from proximal to distal, the improved level of proximal trunk control leads to improvement in distal lower limb control which helped in altering better balance and gait. The relationship between postural control and improved mobility is already established. Through this study we want to improve postural stability through rocker based training and ultimately patient's dynamic balance and gait so functional capability of stroke patients can be enhanced.